A Spotlight on Cholangiocarcinoma

Gastroenterology

Volumn 125, Issue 5, 2003, Pages 1536-1538

  Gores, Gregory J ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; FLUORODEOXYGLUCOSE; GEFITINIB; PHOTOSENSITIZING AGENT; RAPAMYCIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND AGONIST; UNCLASSIFIED DRUG;

ANEUPLOIDY; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; EDITORIAL; ENDOSCOPIC SURGERY; HUMAN; LIVER TRANSPLANTATION; PATHOGENESIS; PHOTODYNAMIC THERAPY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; STENT; SURVIVAL RATE; SYSTEMIC DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0242574419     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gastro.2003.09.008     Document Type: Editorial

References (20)

1. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mossner J. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000;31:291-298.
2. Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc 2001;53:500-504.
3. Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Muller JM, Hortnagl H, Lochs H. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-542.
4. Ortner MA, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125: 1355-1363.
5. Davila JA, El-Serag HB. Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol 2002;97:3199-3200.
6. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-820.
7. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002;37:806-813.
8. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33: 1353-1357.
9. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, Chapman R, Fausa O, Egeland T, Rocca G, Schrumpf E. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-1211.
10. Rumalla A, Baron TH, Riehle D, Harewood GC, Pochron NL, Burgart L, Gores GJ, Therneau TM, de Groen PC, Sebo TJ. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterology Hepatology 2003 (in press).
11. Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, Seese A, Huster D, Berr F. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33:1029-1035.
12. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993;68:874-879.
13. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517; discussion, 517-509.
14. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309-316.
15. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, Chen P, Busuttil RW. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001;7:1023-1033.
16. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002;2:774-779.
17. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(Suppl 6): VI1-9.
18. Baron TH. Chemotherapy impregnated plastic biliary endoprostheses: one small step for man(agement) of cholangiocarcinoma. Hepatology 2000;32:1170-1171.
19. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
20. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet 2003;362:62-64.